Literature DB >> 3514280

Regulation of glomerular filtration rate and sodium excretion by angiotensin II.

J E Hall.   

Abstract

In addition to its extrarenal functions, including the control of arterial pressure and aldosterone secretion, the renin-angiotensin system (RAS) also has multiple intrarenal actions in controlling glomerular filtration rate (GFR) and sodium excretion. Angiotensin II (AngII) helps to prevent excessive decreases in GFR in different physiological and pathophysiological conditions by preferentially constricting the efferent arterioles, an action that can be mediated by either intrarenally formed or circulating AngII. Circulating AngII and intrarenally formed AngII do not appear to directly constrict preglomerular vessels, including the afferent arterioles, when the RAS is activated physiologically. The sodium-retaining action of AngII may be due, in part, to constriction of efferent arterioles and to subsequent changes in peritubular capillary physical forces. However, AngII may also directly stimulate sodium reabsorption in proximal and distal tubules, although the exact site at which AngII increases distal tubular transport is still uncertain. Considerable evidence indicates that the direct intrarenal effects of AngII on tubular reabsorption, including those caused by changes in peritubular capillary physical forces or a direct action on tubular transport, are quantitatively more important than those mediated by changes in aldosterone secretion. Thus, the intrarenal effects of AngII provide a mechanism for stabilizing the GFR and excretion of metabolic waste products while causing sodium and water retention, thereby helping to regulate body fluid volumes and arterial pressure.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514280

Source DB:  PubMed          Journal:  Fed Proc        ISSN: 0014-9446


  16 in total

1.  A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.

Authors:  O Samuelsson; T Hedner; S Ljungman; H Herlitz; B Widgren; K Pennert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  What is the role of the intrarenal renin-angiotensin system in blood pressure control?

Authors:  J E Hall
Journal:  Pediatr Nephrol       Date:  1990-01       Impact factor: 3.714

Review 3.  Intratubular renin-angiotensin system in hypertension.

Authors:  L Gabriel Navar; Hiroyuki Kobori; Minolfa C Prieto; Romer A Gonzalez-Villalobos
Journal:  Hypertension       Date:  2011-01-31       Impact factor: 10.190

Review 4.  Proximal nephron.

Authors:  Jia L Zhuo; Xiao C Li
Journal:  Compr Physiol       Date:  2013-07       Impact factor: 9.090

5.  Resetting of renal autoregulation in conscious dogs: angiotensin II and alpha1-adrenoceptors.

Authors:  P B Persson; H Ehmke; B Nafz; H R Kirchheim
Journal:  Pflugers Arch       Date:  1990-09       Impact factor: 3.657

6.  Renal haemodynamics during hyperchloraemia in the anaesthetized dog: effects of captopril.

Authors:  C S Wilcox
Journal:  J Physiol       Date:  1988-12       Impact factor: 5.182

7.  Mechanisms of blood pressure salt sensitivity: new insights from mathematical modeling.

Authors:  John S Clemmer; W Andrew Pruett; Thomas G Coleman; John E Hall; Robert L Hester
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-12-14       Impact factor: 3.619

8.  Role of endogenous endothelin in renal haemodynamics of newborn rabbits.

Authors:  D S Semama; M Thonney; J P Guignard
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

9.  Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxethy starch (HES 200/0.62, 6%).

Authors:  A C Degrémont; M Ismaïl; M Arthaud; B Oulare; O Mundler; M Paris; J F Baron
Journal:  Intensive Care Med       Date:  1995-07       Impact factor: 17.440

10.  Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.

Authors:  C Rangemark; H Lind; L Lindholm; T Hedner; O Samuelsson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.